Thyroid Eye Disease Market Sees Increased Competition as New Therapies Emerge

DataM Intelligence has released a new competitive intelligence report focusing on the market for Thyroid Eye Disease (TED) treatments. The analysis highlights an evolving landscape where emerging therapies are poised to challenge established treatments.

Thyroid Eye Disease (TED) is an autoimmune condition causing inflammation of the tissues behind the eyes. This inflammation can lead to proptosis (bulging eyes), redness, and swelling. It is the most common cause of orbital inflammation and proptosis in adults, with global prevalence estimated between 90 to 300 cases per 100,000 people.

Currently, the sole FDA-approved treatment for TED in the U.S. is Teprotumumab (Tepezza), marketed by Amgen (formerly Horizon Therapeutics) since 2020. While Tepezza has demonstrated significant efficacy in reducing proptosis and inflammation, its intravenous (IV) administration and reported side effects, such as hearing impairment, have created an opening for alternative treatments with improved convenience and safety profiles.

The pipeline for TED is expanding with several next-generation biologics and novel mechanisms of action. These include Viridian Therapeutics' Veligrotug (anti-IGF-1R) and its subcutaneous (SC) counterpart VRDN-003, aiming for better patient convenience. Other promising candidates involve Immunovant's Batoclimab and argenx's Efgartigimod targeting the FcRn pathway, as well as Roche/Chugai's Satralizumab, an IL-6R inhibitor. An oral small molecule, Linsitinib from Sling Therapeutics, is also in late-stage development.

The report suggests these new approaches, emphasizing SC delivery and novel mechanisms, are likely to reshape the market dynamics. In Europe, Tepezza received a positive opinion from the CHMP in April 2025, with full EMA approval anticipated shortly, but these upcoming therapies may capture significant market share if they offer greater patient benefits.